The aim of the present study was to analyze the action of metformin on short-term memory, glial cell activation and neuroinflammation caused by experimental diabetic encephalopathy in C57BL/6 mice. Diabetes was induced by the intraperitoneal injection of a dose of 90 mg/kg of streptozotocin on two successive days. Mice with blood glucose levels Z200 dl/ml were considered diabetic and were given metformin hydrochloride at doses of 100 mg/kg and 200 mg/kg (by gavage, twice daily) for 21 days. On the final day of treatment, the mice underwent a T-maze test. On the 22nd day of treatment all the animals were anesthetized and euthanized. Diabetic animals treated with metformin had a higher spatial memory score. The hippocampus of the diabetic animals presented reactive gliosis, neuronal loss, NF-kB signaling activation, and high levels of IL-1 and VEGF. In addition, the T-maze test scores of these animals were low. Treatment with metformin reduced the expression of GFAP, Iba-1 (astrocyte and microglial markers) and the inflammation markers (p-IKB, IL-1 and VEGF), while enhancing p-AMPK and eNOS levels and increasing neuronal survival (Fox-1 and NeuN). Treatment with metformin also improved the spatial memory scores of diabetic animals. In conclusion, the present study showed that metformin can significantly reduce neuroinflammation and can decrease the loss of neurons in the hippocampus of diabetic animals, which can subsequently promote improvements in spatial memory.
Introduction
Diabetes mellitus is a metabolic disorder characterized by hyperglycemia and the impaired secretion of endogenous insulin, or insulin receptor insensitivity (ROLL, PALM, 2006) . According to the World Health Organization (WHO), there were 171 million people with diabetes in the year 2000, and by 2030 this number is expected to reach 366 million (World Health Organization, 2006) . Despite this forecast, in 2015 there were already 415 million people with diabetes (International Diabetes Federation, 2015) .
This estimate is important because diabetes is related to secondary complications in various organs, related to angiopathic complications (Kowluru and Kennedy, 2001; Kunisaki et al., 1995) . Hyperglycemia also causes electrophysiological changes (Allen et al. 2004 ) and learning and memory impairment (Jolivalt et al., 2008) in the central nervous system (CNS), which is accompanied by neuronal apoptosis (Sima and Li, 2005) . Neurodegeneration resulting from hyperglycemia is usually associated with chronic inflammatory responses, generated by reactive oxygen species (ROS) and reactive nitrogen species (RNS) (Mello, 2012) .
Hyperglycemia in a culture of endothelial cells induces ROS production, NF-κB activation, increased levels of protein kinase C (PKC) and advanced glycation end products (AGEs). The blockade cell types, such as endothelial and astrocyte, where there is an excess of AGE (Goldin et al., 2006; Zochodne, 2007) . AGE-RAGE binding increases oxidative stress and inflammation mediated by NF-kB (Haslbeck et al., 2004) . NF-κB activation, which can be triggered by both RAGE and VEGF, also increases VEGF expression, leading to a vicious cycle (Evans et al., 2003) . In diabetic RAGE-null mice, no NF-κβ activation or endothelial changes have been detected (Myint et al., 2006; Shoji et al., 2006) .
In the hippocampus of diabetic mice, an inflammatory response occurs alongside astrocyte and microglial activation and increased GFAP and S100B expression, which possibly influences or exaggerates the process of neuronal death (Nagayach; Patro; Patro, 2014; Nardin et al., 2007) . Oxidative stress causes hippocampal neuronal death, as well as a reduction in oligodendrocytes, with a consequent loss of white matter (Francis et al., 2008; Toth et al., 2006) . Many studies have shown a reduction in synaptic proteins such as synaptophysin and synapsin 1 (Duarte et al., 2012; Arnold et al., 2014) , nerve growth factor (NGF) (Sima and Li, 2005) , and learning and memory damage as a result of chronic hyperglycemia (Jolivalt et al., 2008; Sima et al., 2009; Alvarez et al., 2009 ). Inevitably, these changes lead to synaptic communication disorders.
A number of studies have identifies the beneficial effects of metformin, which protects the peripheral vasculature by reducing inflammation induced by NF-κβ activation, as well as benefiting endothelial dysfunction and protecting the peripheral endothelium via the activation of adenosine monophosphate-activated protein kinase AMPK (Correia et al., 2008; Davis et al., 2006; Majithiya and Balaraman, 2006) . However, it is not possible to generalize the data obtained from the peripheral vessels of the CNS, due to the many differences between such vessels and the brain blood vessels (Ge; Song; Pachter, 2005) .
The aim of the present study was to analyze the action of metformin on short-term memory, glial cell activation and neuroinflammation in experimental diabetic encephalopathy in C57BL/6 mice.
Results

Glycaemia and body weight
Fasting glycaemia was measured on day 22 of diabetes induction and 4 h after metformin administration. There was no significant difference between the glucose levels of the control group (107.4 mg/dL 718.10) and the group that received 200 mg/kg of metformin (104.2 mg/dL 715.4). However, there were significant differences (p o0.05) between the STZ (347.75 mg/dL 752.39), STZþM100 (321.57 39.26), STZ þM200 (333.75 mg/dL 756.09) groups and the control groups (control and M200) (Fig. 1) . The same results were observed in all animals after 8 h and overnight fasting (data not shown). The average body weight of the STZ (28.85 70.93), STZþM100 (22.40 7 2.20) and STZþM200 (22.50 72.32) groups at the end of the experiment was significantly lower (p o0.05) than the control group (28.22 70.93) and the M200 group (27.00 73.30) (Fig. 2) .
Metformin improves memory, especially in diabetic animals
The diabetic animals had a significantly lower T-maze score than the animals from the control groups (p o0.05). Treatment with 100 mg/kg of metformin did not improve the performance of the diabetic animals. However, there was a significant increase in the spatial memory score (p o0.05) of diabetic animals that received 200 mg/kg of Metformin. The non-diabetic animals that received 200 mg/Kg of metformin had similar results to the control group (Fig. 3) .
Metformin ameliorated neuron survival in the dentate gyrus in mice with diabetes induced by STZ
Immunohistochemistry analysis for FOX-1 revealed a constitutive stain on the mature pyramidal neurons located in the molecular area (arrow) and on the granulated neurons in the dentate gyrus (asterisk) of control group animals (Fig. 4A) . The non-diabetic animals that received 200 mg/Kg of metformin exhibited the same staining pattern as the control group, which indicates the preservation of neuron morphology (Fig. 4B) . The staining intensity of mature neurons was lower (p o0.05) in the diabetic animal group than in the control group (Fig. 4C) , and there was no significant difference between the STZ þ M100 group (Fig. 4D ) and the STZ group. On the other hand, staining intensity increased (p o0.05) following 200 mg/Kg metformin treatment in diabetic animals (Fig. 4E) . The NeuN marker is a protein produced by mature neurons. After 200 mg/Kg of metformin, the staining intensity of NGF did not differ from the control group ( Fig. 5A and B) . The staining intensity of the adult neurons in the diabetic group was significantly lower (p o0.05) than in the control and M200 groups. The result of the STZþM100 group was similar to the STZ group (Fig. 5D ). When the diabetic animals were treated with 200 mg/Kg of metformin (Fig. 5E ), staining intensity increased significantly (p o0.05) in comparison with the STZ and STZþM100 groups, and was similar to the control and M200 groups.
Neuronal growth factor (NGF) is an important factor in neuron survival, differentiation of cells in the CNS and neuron precursor differentiation (Sofroniew et al., 2001) . In diabetic animals, the staining intensity of NGF did not differ from the control group ( Fig. 6A and B) . However, the STZ þ M100 group displayed a significant increase in immunostaining (p o0.05) (Fig. 6C) . Interestingly, the STZþM200 group showed a reduction in NGF staining when compared to the STZ þ100 group. This data was confirmed by Western Blotting analysis (Fig. 6F) .
2.4. Metformin reduces astrocyte and microglia activation in the dentate gyrus area of the hippocampus Glial fibrilar acid protein (GFAP) is a protein expressed in astrocytes and its increase is indicative of astrocyte activation, which is often termed reactive gliosis. Activated astrocytes present some peculiar morphologic characteristics, differing from non-activated astrocytes. Once activated, astrocytes have a shorter cytoplasmic extension, as shown in Fig. 7A . The diabetic animals presented a significantly higher expression of GFAP, and also presented a phenotype characteristic of cellular activation (Fig. 7C) . Only the 200 mg/kg of the metformin treatment group resulted in a significant reduction of reactive gliosis (p o0.05) in the diabetic group (Fig. 7D) . Astrocyte activation in animals from the M200 group was not significantly different from that of animals from the control group (Fig. 7B) .
The Iba-1 protein is a distinct marker of microglia, which are immune specific cells of the CNS. Microglia play an important role in protecting the brain tissue from injuries. In cases of hyperglycemia, the microglia become activated, releasing stimuli for their own proliferation, followed by morphological changes ( Fig. 8-B ). The STZ group showed significant microglia activation (p o0.05) in comparison with the control and M200. Both of the metformin treatment groups resulted in a significant reduction (p4 0.05) in microglia activation in diabetic animals. The animals from the STZþ M100 and STZþM200 group presented the same level of Iba-1 as the control groups and M200 group (Figs. 8A and 8E, respectively).
Metformin decreases apoptosis in the hippocampus of diabetic mice
Chronic hyperglycemia is directly associated with neuronal apoptosis of the hippocampus, which causes cognitive impairment. Expression of the pro-apoptotic protein Bax (Fig. 9A ) and the anti-apoptotic protein Blc-2 ( Fig. 9B ) were quantified by immunoblotting. In the control group, expression of both proteins was at physiologic levels ( Fig. 9) . The STZ group displayed a significant increase in Bax and Blc-2 (p o0.05). The expression of the Bcl-2 protein was significantly increased only in the STZ þ M100 group in comparison with the STZ group.
Metformin increases p-AMPK and eNOS expression and reduces vascular permeability
AMPK is a protein that regulates energy metabolism and is either activated by phosphorylation when levels of ATP decrease inside the cell or pharmacologically. Metformin is a drug which acts through the activation of AMPK Santomauro et al., 2008) . In the control group, p-AMPK was expressed at physiologic levels. In the STZ and STZ þ M100 groups, there was no significant increase in levels of the p-AMPK protein in comparison with the control group (Fig. 10) . In contrast, the STZþM200 group displayed a significant increase of p-AMPK when compared to the other groups, confirming its pharmacological activation (Fig. 10) .
The p-AMPK pathway has been shown to activate the eNOS enzyme, which subsequently activates the phosphorylation of AMPK, causing a positive feedback loop. The control and diabetic groups presented a basal level of eNOS. Both Metformin treatment groups exhibited a significant increase (p o0.05) in eNOS expression in comparison with the diabetic group (Fig. 11A ). The data also shows that eNOS activation was not related to the pathogenesis of diabetes, even though the increase in p-AMPK expression induced by metformin helped to increase eNOS expression.
VEGF is a pro-angiogenic protein that acts in the endothelial tissue. During acute inflammation, VEGF increases vascular permeability. The pathology of diabetes has many secondary complications, which derive from micro and macro vessel modification, due to increased vascular permeability and endothelial dysfunction. Levels of VEGF were significantly higher among diabetic mice than in the control group (p o0.05). Similar results were observed when the STZþM100 group was analyzed, which may be related to endothelial permeability. The 200 ml/kg metformin treatment group displayed a lower expression of VEGF than the STZ group (po 0.05). No significant statistical difference was found between the STZ þ M200 and the control groups (Fig. 11B) . The findings of the present study suggest that metformin can recover reductions in VEGF levels caused by STZ exposure.
Metformin decreases Iκβα phosphorylation in diabetic mice
The expression of the NFκB inhibitor Iκβα was evaluated using immunoblotting. The phosphorylation of Iκβα stimulates the activation of NFκB, initiating the pro-inflammatory cascade. The phosphorylation of Iκβα was higher in the STZ group than the control group (p o 0.05). Treatment with 100 and 200 mg/kg of metformin resulted in a significant reduction in Iκβα activation in comparison with the STZ group (p o 0.05) (Fig. 12A) .
The activation of NFκB was significantly greater in the STZ group than in the control group (p o 0.05), indicating the translocation of the transcription. None of the treatments significantly reduced NFκB (Fig. 12B) . The expression of IL-1β was greater in the STZ group than in the control group, which indicates inflammation in the hippocampus. Only the STZ þM200 group had significantly (p 4 0.05) lower IL-1β levels than the other groups (Fig. 13) . 
Discussion
Metformin hydrochloride, which acts mainly through AMPK activation, is the most widely prescribed drug for patients with type 2 diabetes (DMT2). Mice that are fed an atherogenic diet follow a model that mimics the characteristics of DMT2. Studies assessing cognitive impairment by HFD-induced diabetes have considered variations in the type and consumption time of the diet, as well as in mouse lineage, which results in different effects on the CNS (Arnold et al., 2014) . Contrastingly, the experimental model of type 1 diabetes mellitus (DMT1) induced by STZ is a widely used method for evaluating changes in the CNS caused by hyperglycemia (Hernández-Fonseca et al., 2009; Ye et al., 2011; Nagayach et al., 2014) . Although some authors have used STZ to induce neurotoxicity in vivo (Pathan et al., 2006; Islam et al., 2013) and in vitro (Plaschke and Kopitz, 2014) via intracerebroventricular administration, others have administered STZ via intraperitoneal injection as a disruptor of insulin signaling to induce memory impairment (Jolivalt et al., 2008; Alvarez et al., 2009; Jolivalt et al., 2010) and reduce hippocampal neurogenesis (Beauquis et al., 2008; Beauquis et al., 2010) . Jolivalt and Cols (2010) demonstrated that two intraperitoneal injections of STZ in C57Bl/6 mice induced insulin signaling impairment associated with learning and memory deficits.
The activation of AMPK has been found to have positive effects on CNS neuronal survival (Amato and Man, 2011) , as well as modulating long-term potentiation (LTP) (Potter et al., 2010) , neurogenesis and the formation of spatial memory (Wang et al., 2012) . The effects of AMPK activation by metformin on cognitive impairment caused by hyperglycemia or insulin resistance are controversial. According to studies by Pintana et al. metformin was able to reduce the glycemic level and cognitive impairment in animals fed with an atherogenic diet. (Pintana et al., 2012) . On the other hand, a study by McNeilly et al., found that dietary supplementation with metformin did not attenuate cognitive impairment in animals fed with HFD, even though it improved glycemic control (McNeilly et al., 2012) .
In the diabetes induced by STZ model, insulin secretion and signaling are impaired as there is destruction of β cells in the pancreas, characteristic of type 1 diabetes mellitus (DMT1). The presence of insulin resistance, and the fact that metformin improves the sensitivity of the insulin receptor, has been proven by using an experimental model of DMT2 induced by HFD (Skovsø, 2014) . To significantly reduce the glycemic level in animals with DMT1 induced by streptozotocin, as well as improve cognitive impairment, Bhutada et al. used a dose of 500 mg/Kg of metformin per day (Bhutada et al., 2011) . However when considering dose adjustments based on the metabolism of mice in relation to human doses, 500 mg/kg of metformin for testing in mice is very high (Kamboj et al., 2013) . In the present study, therefore, metformin hydrochloride did not reduce glycemic levels in diabetic animals induced by STZ, most likely due to the lack of insulin associated with the destruction of pancreatic β cells.
Recent studies have shown that from a range of several antidiabetic drugs, metformin can promote neuronal survival and lead to a significant improvement of memory and cognition (Patrone et al., 2014) . Experiments by the authors of the present study analyzing the spatial memory of diabetic animals have revealed that there is damage to memory in such cases, and that a dose of 200 mg/Kg of metformin in diabetic animals improved the damage caused by hyperglycemia, independent of glycemic control. This data indicates that metformin has a beneficial effect on memory formation and inflammation. Evidence has shown that metformin promotes neurogenesis (Potts and Lim, 2012) , while studies of the action of metformin on memory formation in experimental models of Alzheimer's disease have produced inconclusive results (Salminen et al., 2011) . Despite this, an epidemiological study by Moore et al. indicated that the administration of metformin in diabetes patients increased the risk of cognitive impairment (Moore et al., 2013) . It should be noted, however, that the evidence from this study was not sufficiently robust to prove that metformin causes cognitive deficits in diabetic patients, as the authors did not produce data regarding the duration and severity of the diabetes, the duration of treatment with metformin, and the use of other hypoglycemic agents (Goodarzi, 2014 ). The present study shows that the animals from the M200 group did not display any loss of spatial memory, or observe the activation of astrocyte microglia.
The antibody used in this study was anti-FOX-1, which is able to detect other protein members from the FOX family, namely FOX-1, FOX-2, FOX-3, FOX-4 and FOX-5. Recent studies have shown that the FOX-3 protein is the marker of the nucleus of mature neurons NeuN (Kim et al., 2009; Dent et al., 2010) . Therefore, the anti-FOX-1 antibody was used to analyze neuronal loss in this study, indicating that treatment with 200 mg/kg of metformin was more effective at conserving pyramidal neurons in the dentate gyrus of diabetic mice. Similar results were obtained with immunofluorescence for Neu-N, a marker of mature neurons.
Although the animals with diabetes induced by STZ displayed high Bax levels, no change in Bcl-2 expression was observed. This data confirms the findings of Sima and Li (2005) , whose analysis in a spontaneous model of diabetes in BB/Wor mice also demonstrated increased Bax expression, without any alteration in the expression of the mitochondrial apoptosis protein Bcl-xL (Sima and Li, 2005) . Studies examining endothelial cells have shown that metformin can reduce apoptosis both in vitro and in vivo (Davis et al., 2006) . The present study found that although treatment with metformin tended to reduce Bax levels, there was no significant change in comparison with the diabetic group. Contrastingly, treatment with 100 mg/Kg of metformin induced higher levels of Bcl-1, indicating that metformin appears to have an antiapoptotic effect on neuronal cells, while treatment with 200 mg/ Kg of metformin did not result in an increase of Bcl-2 expression, potentially due to the negative feed-back mechanism of the apoptosis signaling pathway. Similar results were obtained from analysis of the expression of NGF, an important marker of neuronal survival, suggesting that metformin reduces apoptosis and regulates the proliferation of neuronal processes. Various experimental models have reported astrogliosis in the brains of animals. This is associated with cognitive impairment (Revsin et al., 2005; Duarte et al., 2012; Colangelo et al., 2014) and the activation of microglia associated with inflammation (Dheen et al., 2007; Nath et al., 2009) . Recent studies have shown that the activation of AMPK for resveratrol in a diabetes model induced by streptozotocin reduced astrogliosis (Jing et al., 2013) . The present study found that pharmacologic activation of AMPK by metformin can produce similar effects, as well as reducing the reactive gliosis of diabetic animals.
The present study is the first to report the effect of metformin on microglia in vivo. Studies in vitro have shown that metformin inhibits the activation of activated microglia by LPS in the independent mode of AMPK (Łabuzek et al., 2010) . At the same time, the activation of AMPK by resveratrol produced the same effect in cells of microglia activated by morphine in vitro (Han et al., 2014) . The in vivo results of the present study agree with the in vitro findings, which show that metformin reduces inflammation and activation of microglia cells.
The transcription factor NFκB promotes the transcription of inflammatory cytokines when activated. NFκB is a dimer located on the cytoplasm that is linked to its inhibitory molecule Iκβα. Phosphorylation of Iκβα by Kinases IK (IKK) promotes the degradation of Iκβα by the proteasome, with NFκB subsequently activated by phosphorylation. The activated NFκB is translocated to the nucleus where it promotes the transcription of inflammatory proteins, such as IL-1β, IL-6 and TNF-α (Hayden and Ghosh, 2008) . Although NFκB activates the transcription of the IL-1β gene, post-transcriptional modifications are necessary in order to facilitate the release of IL-1β from the inflammation complex. Studies in vitro have shown that metformin treatment resulted in increased IL-1β expression, without the activation of NF-kB in microglia by LPS (Łabuzek et al., 2010) . However in the present study, metformin decreased phospho-Iκβα expression and negatively regulated the active form of IL-1β (17 KDa), resulting in cleavage of the IL-1β inactive form (31 KDa) by CASPASE 1 (Piccioli and Rubartelli, 2013) . The results show that metformin acts as a modulator for the activation of IL-1β in an NFκB dependent mechanism in the hippocampus cells in diabetic animals. In the hippocampus of diabetic animals treated with metformin, the expression of eNOS was observed with both doses, which may have a beneficial effect on endothelial function. The activation of eNOS has been strongly associated with endothelial survival and angiogenesis promoted by increased VEGF expression (Dimmeler et al., 2000) . However, in diabetic patients, metformin appears to improve endothelial function and reduces VEGF expression (Ersoy et al., 2008 ). This study also shows that the hippocampus of diabetic animals treated with 200 mg/Kg of metformin underwent a significant reduction of VEGF. According to Jing et al. (2013) , the reduction of this growth factor by the activation of AMPK during diabetes may indicate improvement in endothelial function and the blood brain barrier (Jing et al., 2013) . Furthermore, VEGF can increase the permeability of the blood brain barrier by reducing the expression and arrangement of occludin protein and ZO-1 at the junction of the brain endothelial cells (Fischer et al., 2002) . Therefore, the increase in angiogenesis via eNOS without the up regulation of VEGF expression is an interesting feature observed in the induction of angiogenesis, as it increases the permeability of vessels and inflammation (Chung et al., 2008; Chung et al., 2010) .
The capacity of metformin to promote neurogenesis is potentially promising for the treatment of patients with cognitive impairment associated with DMT1 and DMT2. The effect of this drug on cognitive impairment induced by hyperglycemia has been little explored. The present study found that metformin can significantly reduce neuroinflammation and decrease the loss of neurons in the hippocampus of diabetic animals, which can subsequently promote improvements in spatial memory. Comparisons between 100 and 200 mg/Kg showed that the latter resulted in a more effective outcome in STZ experimental analyses. In conclusion, metformin may be a therapeutic alternative for patients with DMT1 who present cognitive impairment. However, further studies are required to evaluate the effect of joint treatment with metformin and insulin in the short and long term.
Experimental procedure
Experimental design
Fifty C57BL/6 male mice aged 12-14 weeks and weighing 25-30 g were used in all experiments. All animals received standard food and water and were kept at a temperature of 22°C and a light/dark cycle of 12 h. They were distributed into five experiment groups: I. Control, II. Metformin 200 mg/Kg, III, Streptozotocin, IV. Streptozotocin þ metformin 100 mg/Kg and V. Streptozotocinþ Metformin 200 mg/Kg. Classical metabolic studies describe the total metabolic rate of a 30 g mouse as 961 kJ per kg of body weight, which is approximately seven times the total metabolic rate of a 70 kg human (138 kJ per kg) (Terpstra, 2001) . In the present study, the doses chosen (100 mg/Kg and 200 mg/Kg) were based on equivalent doses (700 mg/Kg and 1400 mg/Kg) given to humans.
Diabetes was induced as per the protocol described previously by Jolivalt et al. (2010) , with modifications. Briefly, Streptozotocin (STZ) was administered by intraperitoneal injection at a dose of 90 mg/kg dissolved in citrate buffer pH 4.5 on two successive days, after overnight fasting. Control and metformin 200 mg/kg groups received only the vehicle (citrate buffer). On the fourth day after induction, a tail puncture was performed to confirm the diabetes induction using a One Touch Ultra Lifescan (J & J) glucometer. Mice with blood glucose levels Z 200 dl/ml were considered diabetic and were given metformin hydrochloride dissolved in distilled water at doses of 100 mg/kg and 200 mg/kg (gavage twice daily) for 21 days. On the final day of treatment, the mice were subjected to a T-maze test. All animals were anesthetized and euthanized on the 22nd day. Blood glucose and weight were monitored weekly. The experiment was approved by the Research Center Aggeu Magalhães Ethics Committee/Oswaldo Cruz Foundation (46/2013-CEUA/FIOCRUZ).
Behavioral testing (T-maze)
Hippocampal damage to the short-term or working memory was assessed by subjecting mice to a spontaneous T-maze test. Briefly, the mice undergo a maze challenge, with their natural tendency being to enter the goal arm of the maze where they have previously spent most time. Therefore, the animals need to remember which was the last arm they visited (Sharma et al., 2010) . The animals were placed in the T-maze one day before performing the task in order to allow them to become accustomed to the environment. During the test each mouse was placed in the base arm of the T-maze and allowed to select a goal arm to enter. Once the mouse had chosen a goal arm, it was confined to this arm for 30 seconds before returning to the base arm. The mouse was then allowed to explore the maze for 2 min.
Immunohistochemistry
Following anesthesia, the animals were transcardially perfused with physiological saline (20 ml), followed by 4% paraformaldehyde (Sigma-Aldrich) (40 ml) in 0.1 M phosphate (sodium phosphate monobasic and dibasic heptahydrated -Sigma-Aldrich) buffered saline (PBS), pH 7.2. The cerebrum of each mouse was immediately removed and post-fixed overnight in the same fixative. The samples were dehydrated in a series of ethanol rinses (Isofar Chemical Co., RJ, Brazil), cleared in xylene and embedded in paraffin (Merck, USA). Sections with a thickness of 5 mm were cut on an RM 2035 microtome (Reichert S, Leica), re-hydrated, and treated with 20 mM citrate buffer, pH 6.0, at 100°C, for 30 min Endogenous peroxidase was blocked with 3% hydrogen peroxide H 2 O 2 and the sections were blocked with 1% bovine serum albumin (BSA, fraction V) (Miles, Naperville, IL, USA) for 1 h at room temperature. All groups were incubated with the following mouse polyclonal primary antibodies: VEGF (Abcam, catalog number ab1316, USA), rabbit polyclonal primary antibodies NGF (Abcam, catalog number ab6199, USA), FOX1 (Santa Cruz Biotechnology, catalog number 135476, CA, USA,) and GFAP (DakoCytomation, catalog number: ZO 334, CA, USA). All antibodies were added at 1:100 dilution, overnight at 4°C. After washing, the sections were overlaid with a biotin-conjugated secondary antibody for 1 h (DakoCytomation, Biotinylated Link Universal HRP; catalog number: K0690, CA, USA), and visualized with 30-3-diaminobenzidine (DAB) as the chromogen. The slices were counter-stained with Harris' hematoxylin and mounted in Entellan (Merck, catalog number: 1079610100, USA). Pixel density was measured in five stained areas using the GIMP 2.6.11 software (GNU Image Manipulation Program software, CNET Networks, Inc. Australia).
Immunofluorescence
Following anesthesia, the animals were transcardially perfused with physiological saline (20 ml), followed by 4%
paraformaldehyde (Sigma-Aldrich) (40 ml) in 0.1 M phosphate (sodium phosphate monobasic and dibasic heptahydrated -Sigma-Aldrich) buffered saline (PBS), pH 7.2. The cerebrum of each mouse was immediately removed and post-fixed in the same fixative overnight. The samples were dehydrated in a series of ethanol rinses (Isofar Chemical Co., RJ, Brazil), cleared in xylene and embedded in paraffin (Merck, USA). Sections with a thickness of 5 mm were cut on an RM 2035 microtome (Reichert S, Leica), rehydrated, and treated with 20 mM citrate buffer, pH 6.0, at 100°C, for 30 min After, they were permeabilized with 0.5% Triton X-100 and incubated for 1 h with blocking solution (3% BSA plus 0.2% Tween 20 in Tris buffered saline). Subsequently, the sections were incubated with anti-NeuN antibodies (Abcam, catalog number: 104225) at a dilution of 1:100. The primary antibodies were incubated overnight and then incubated with polyclonal fluor 546-conjugated secondary antibody (Alexa, catalog number A10040) against rabbit immunoglobulin for 1 h. The slices were washed and mounted in fluorescent Prolong Gold Antifade medium (Life Technologies, catalog number: P36930) for observation under an inverted fluorescence microscope (Zeiss MicroImaging GmbH) equipped with a camera (Zeiss AxioCam MRM) and the Re-lease 4.7.2 image analysis software program. Pixel density was measured in five stained areas using the GIMP 2.6.11 software (GNU Image Manipulation Program software, CNET Networks, Inc. Australia).
Western blot
The hippocampi were rapidly dissected and homogenized in an extraction containing protease inhibitor cocktail (10 mM EDTA, Amresco, Solon, USA; 2 mM phenylmethane sulfonyl-fluoride, 100 mM NaF, 10 mM sodium pyrophosphate, 10 mM NaVO 4 , 10 mg of aprotinin/ml and 100 mM Tris, pH 7.4 -Sigma-Aldrich). The samples were mixed and homogenized to form a pool from each group. Homogenates were centrifuged and frozen at À 80°C. A quantity of 40 mg of the total protein was loaded into each well in an electrophoresis gel and separated, before being electrophoretically transferred onto nitrocellulose membranes (BioRad, catalog number 162-0115). After blocking with 5% skim milk, the membranes were incubated for 2 h with rabbit polyclonal antibody from Abcam (CA, USA) against BAX (catalog number ab7977), BLC-2 (catalog number ab7973), NGF (catalog number ab6199), eNOS (catalog number ab66127) and p-NF-κB (catalog number ab97726), together with rabbit monoclonal antibody against AMPK (ab32047), mouse polyclonal antibody against VEGF (catalog number ab1316), and p-IKb (Cell Signaling, catalog number 9246L, MA, USA), p-AMPK (Cell Signaling, catalog number 2535s, MA, USA), TNF-α (Peprotech, catalog number: 500-P64, NJ, USA), IL-1β (GenWay Biotech, catalog number: 18-732-292194I, CA, USA), and IκB (Santa Cruz Biotechnology, CA, USA, catalog number sc-371). All the primary antibodies were diluted in blocking solution (1% bovine serum albumin, 0.02%phosphate buffered saline and 0.01% Tween) at a 1:1000 dilution factor. Following washing, the membranes were incubated with horseradish peroxidaseconjugated (HRP) anti-rabbit (Abcam, catalog number: ab6721, UK) and anti-mouse (Sigma-Aldrich, catalog number: A0168, USA) secondary antibodies in a 1:1000 dilution. Chemiluminescence reagent (Super Signal, Pierce, catalog number: 34080, USA) was added for protein band illumination, and blots were developed on X-ray film (Fuji Medical, Kodak, catalog number: Z358487-50EA, Japan). For quantification, densitometry values were obtained by measuring the pixel density of each band using Image J 1.38 software (NIH, MD, USA). For each protein investigated, the results were confirmed in three sets of experiments. Immunoblotting for β-actin was performed as a control gene for the aforementioned blots. After visualization, the membranes were stripped and reprobed with monoclonal anti-β-actin antibody in 1:1000 dilution (Sigma-Aldrich, catalog number A2228, USA) and protein densitometry was performed. The ratio of each protein/β-actin studied was calculated and compared between the groups.
Statistical analysis
For immunofluorescence and immunohistochemistry, pixel density was measured in five stained areas using a software program (GIMP 2.8.14). The densitometric values of the immunoreactive bands (immunoblotting), immunohistochemistry and immunofluorescence were analyzed with the GraphPad Prism software package V6.0 (San Diego, CA, USA). One-way analysis of variance (ANOVA), followed by Dunnett's and/or Tukey's post-hoc tests were used to compare groups. The results were expressed as means 7S.D. All analyses were performed using p-value o 0.05 statistical significance.
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